Key Highlights

● A brokerage downgraded the stock to Hold and cut its target to $46 from $56.

● Third-quarter Revenue of $5.14 billion rose only 1.4% year over year.

● Full-year 2026 adjusted EPS guidance was cut to $3.16 to $3.18.

● A Cybersecurity outage reportedly cost about $150 million in third-quarter sales.

Boston Scientific (NYSE:BSX)'s difficult week continues. A brokerage downgraded the medical-device maker to Hold from Buy on Friday and cut its price target to $46 from $56, according to media reports and market data. No pre-market quote was available, so the stock's direction before the open has not been confirmed. Market data gave a reference price of $42.69, against which the new target implies about 7.8% upside.

Why analysts are backing off

The downgrade follows a third-quarter report on Wednesday, October 28, that disappointed investors. According to market data, adjusted EPS was $0.73, in line with consensus and down from $0.75 a year earlier. Revenue was $5.14 billion, slightly above the $5.09 billion estimate, but up only 1.4% year over year, a sharp slowdown for a company that had been one of the faster growers in large-cap medtech.

The guidance caused the most damage. Boston Scientific cut its full-year 2026 adjusted EPS forecast to $3.16 to $3.18, below what investors expected, and guided to fourth-quarter EPS of $0.77 to $0.79. Market data said fourth-quarter sales could fall from a year earlier.

Market data also listed several specific problems. A cybersecurity outage lasting about eight days reportedly cost about $150 million in third-quarter sales. There is weakness in electrophysiology and in the WATCHMAN heart device, pricing pressure in China, and a risk that growth will be flat in 2027. Market data reported that management expects a growth low point in 2027 before a recovery toward 2030.

The brokerage is not alone. Market data lists a series of moves this week: one brokerage downgraded to Neutral with a $46 target, another moved to Market Perform, and five others all cut their targets. One more brokerage, by contrast, raised its target to $51 and kept a positive rating.

The consensus is still "Moderate Buy," with an average target of $61.53, well above the current price. That gap suggests more target cuts may follow as other firms update their models after the guidance reset. The count shows 1 Strong Buy, 20 Buy, 8 Hold and 2 Sell ratings, so the balance of opinion is still positive, but it has shifted quickly this week.

A shrinking S&P 500 heavyweight

Boston Scientific is an S&P 500 member, and market data now puts its Market Value at about $61.9 billion. The stock's one-year range runs from a high of $105.65 to a low of $39.57, which means the shares have lost more than half their value at the low end of that range. The 50-day Moving Average of $44.93 is well below the 200-day average of $57.15, a sign of how fast the decline has been.

The pressure extends across medtech. A brokerage downgraded Stryker (NYSE:SYK) to Hold on Friday, and one report said Stryker was down about 11% before the bell. The broader market is weak as well, with S&P 500 futures down about 1% early Friday as tech sold off after Amazon (NASDAQ:AMZN)'s and Intel (NASDAQ:INTC)'s results.

Risks and what to watch

The bear case is that Boston Scientific's key growth drivers, electrophysiology and WATCHMAN, are slowing at the same time, with 2027 shaping up as a flat year. The bull case is that the cyber outage was a one-time event, the valuation has reset sharply (market data lists a P/E of about 18), and management still expects growth to recover later in the decade.

Watch whether the stock holds above its recent lows once trading opens and whether more Brokers cut ratings. The fourth-quarter report early in 2027 will show whether management can meet its reduced guidance.